Pituitary function in adult males receiving medroxyprogesterone acetate.
The pituitary, adrenal, and gonadal functions of nine males (six XY, two XYY, and one XY/XYY) were studied after at least 6 months of medroxyprogesterone acetate (MPA) therapy for antisocial or sex-offending behavior. Five were studied both before and during therapy, four only during therapy. MPA was effective in decreasing serum gonadotropin and plasma testosterone concentrations. MPA caused no change in the 24-hour rhythm or total integrated concentration of growth hormone. The plasma cortisol circadian rhythm was suppressed but not obliterated by MPA therapy. Although a significant decrease (P less than 0.001) in 24-hour integrated concentrations of plasma cortisol was also found, the rise in the plasma cortisol level after insulin-induced hypoglycemia was unchanged.
D000302:Adrenal Cortex / Q000187:drug effects; D000328:Adult; D000987:Antisocial Personality Disorder / Q000188:drug therapy; D002940:Circadian Rhythm / Q000187:drug effects; D005640:Follicle Stimulating Hormone / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008525:Medroxyprogesterone / Q000494:pharmacology* / Q000627:therapeutic use; D010262:Paraphilic Disorders / Q000188:drug therapy; D010902:Pituitary Gland / Q000187:drug effects*; D010903:Pituitary Gland, Anterior / Q000187:drug effects; D010913:Pituitary-Adrenal System / Q000187:drug effects; D013312:Stress, Physiological / Q000503:physiopathology; D013739:Testosterone / Q000097:blood
D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone; D008525:Medroxyprogesterone; D006854:Hydrocortisone